Innovations and Challenges in Osteoporosis: A Review of Current and Future Strategies

Abstract

Osteoporosis is a chronic skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased fragility and fracture risk. This review provides a comprehensive overview of the pathophysiology, diagnostic approaches, and therapeutic strategies for osteoporosis, highlighting the advancements in research and emerging treatment paradigms. Key findings emphasize the critical role of hormonal regulation, molecular pathways such as RANK/RANKL/OPG and Wnt/β-catenin signaling signaling, and the influence of inflammation on bone remodeling. Current pharmacological treatments, including anabolic and anti-resorptive agents, have been explored alongside promising innovations such as dual-action drugs, sclerostin inhibitors, and nanoparticle-based delivery systems. Additionally, herbal therapies have been discussed as complementary alternatives, offering bioactive compounds that modulate bone remodeling pathways.
Emerging technologies, such as 3D-printed bone models and CRISPR-Cas9 gene editing, are transforming preclinical research, addressing the limitations of traditional models, and bridging the gap to clinical applications. Despite these advancements, challenges such as adherence to therapy, accessibility to low-resource settings, and ethical considerations in animal research remain significant barriers. Future research should focus on developing standardized protocols for novel therapies, conducting large-scale clinical trials, and leveraging personalized medicine and artificial intelligence to optimize osteoporosis care. This review underscores the need for a multidisciplinary approach to effectively address the global burden of osteoporosis, reduce fracture risk, and improve the quality of life of affected individuals